Webinar 5 - What do we do now that the Long Acting Growth Hormone is here?
The ESPE Education and Training Committee are pleased to announce the fifth ESPE Connect Webinar:
Date: Wednesday 25th May 2022
Time: 16:00-17:30 CET /15:00-16:30 BST / 09:00-10:30 CDT
- Welcome - Dr. Senthil Senniappan, Liverpool, UK (ESPE Connect Webinar Convenor)
- Introduction to the webinar - Professor Bradley Miller, Minneapolis, USA
- Long-acting GH therapy for pediatric GH deficiency: What are the current data and rationale? Dr. Aristides Maniatis, Colorado, USA
- How to monitor IGF1 and What's the future of LAGH? Professor Bradley Miller, Minneapolis, USA
- Panel Discussion – All
- Webinar Close
Professor Bradley Miller
Dr. Miller earned both his medical and PhD degree (Pharmacology) from the Medical University of South Carolina in Charleston, SC. His medical training includes a pediatric residency and pediatric endocrinology fellowship at the Mayo Graduate School of Medicine in Rochester, MN. Board certified in pediatrics and pediatric endocrinology, Dr. Miller joined the University of Minnesota Medical School in 2003, where, besides holding the role of Professor with the Department of Pediatrics, he is also Director of the Division of Pediatric Endocrinology and Director of both the Pediatric Growth Program and the Pediatric Bone Clinic.
Dr. Miller has an interest in the role of the growth hormone/IGF system and the regulation of growth at the growth plate in normal and abnormal growth in children. Dr. Miller is also interested in the bone health, adrenal function, growth, and pubertal development of children with rare diseases and following adversity including hematopoietic stem cell transplant, cancer and its therapies, fetal alcohol exposure, premature birth and international adoption. Dr. Miller has been an investigator in numerous clinical trials developing new therapies for children and adults with rare diseases. Dr. Miller has more than 80 publications in peer-reviewed journals and has been invited to speak internationally about therapy for growth disorders in children.
Dr. Aristides Maniatis
Dr. Maniatis attended Harvard Medical School and completed his pediatrics residency and pediatric endocrinology fellowship at Children's Hospital Colorado, USA. He is in private practice at Rocky Mountain Pediatric Endocrinology in Colorado. He is also an Associate Clinical Professor with the University of Colorado Health Sciences Center. In addition, he runs the follow-up program for congenital hypothyroidism with the Colorado Newborn Screening Program.
He is a national key opinion leader on growth disorders and has served as national spokesperson for Growth Awareness Week (2018-2021). He is a principal investigator for an epidemiologic study in type 1 diabetes, a phase 4 trial for hypophosphatasia, and all current phase 3 trials in long-acting growth hormone (Ascendis, Novo Nordisk, and OPKO/Pfizer; in alphabetical order). He is also on the adjudication committee for the phase 3 trial of macimorelin as a testing agent. Dr. Maniatis lectures extensively and has several publications to his credit.
- Discuss challenges of current daily GH therapy
- Discuss principles of long-acting GH therapy development
- Discuss current landscape of long-acting GH therapies either approved or in development
This webinar was kindly supported by a grant from Pfizer.
If you’re an ESPE member all of our ESPE Connect webinars will be free to attend. If you’re not a member you can join here or you can register for a small fee of €25.
Become an ESPE member here